In 2003, Hefei High-tech Financing Guarantee Co., Ltd. came into being with the strong support of the Management Committee of Hefei High-tech Zone. Focusing on high-tech small and medium-sized enterprises in the high-tech zone, it provides them with financing guarantee services throughout the life cycle. After 19 years, the high-tech guarantee service has accumulatively served more than 4,500 enterprises.

Ten years of wind and rain in Hefei High-tech Zone has written the spring and autumn, and ten years of struggle have created brilliance. On this occasion, Gaoxin Guarantee specially launched a series of reports entitled "Ten Years of Companionship·Financial Power Behind the Enterprise", telling the little-known but magnificent story of guarantee and enterprise accompanying each other.

Knowing its shallowness but not knowing its depth is still unknown; knowing its partiality but not knowing the whole is still unknown.

Everyone has this kind of personal experience. When we walk into the hospital, the last thing we want to hear is "You have to be mentally prepared. It may be a certain disease, but it cannot be diagnosed yet..." An inaccurate answer is worse than a bad one. The news is even more disturbing, and it may also delay the best treatment time. In the eyes of ordinary people, the so-called development of medicine should mean a one-shot diagnosis and one-shot effective treatment.

Undoubtedly, the value of diagnosis lies in "knowing" and giving definite answers. For this lofty goal, fortunately, a local company in Anhui has been on the way.

Wang Zhongliang, who graduated from clinical medicine of Anhui University of Traditional Chinese Medicine, worked as a doctor in a hospital, worked in the Institute of Biophysics of the Chinese Academy of Sciences, and founded biomedical companies in Beijing, Hebei, Anhui and other places. His years of experience in the medical industry made him aware of To the rapid development of the in-vitro diagnostic industry, and compared with foreign countries, the domestic in-vitro diagnostic market is insufficient. The so-called in vitro diagnosis refers to the diagnosis made by taking blood, body fluid, and tissue samples out of the human body for testing, so that they can intervene in diseases as early as possible and take the initiative to control the health status.

The rapid growth of China's IVD market is mainly due to the rapid economic development, the increase of wealth and middle-income groups, the reduction of infectious diseases, the extension of life expectancy, and of course the huge population base. However, the market still faces challenges such as uneven distribution of medical resources, bottlenecks in the reform of the medical system, and the lack of professional medical equipment and talents to meet the growing demand. China is almost completely dependent on foreign countries in the field of biomedical raw materials. In 2013, Wang Zhongliang, who has accumulated a lot of experience in product research and development, preparation of biological raw materials, marketing and team management, quickly led the R&D team and expert team to form Anhui Huibang Bioengineering Co., Ltd. Diagnostic reagent raw materials, products and equipment.

秉持“济世于心,惠民兴邦”，以及为促进国内体外诊断市场发展贡献本土力量的信念，惠邦生物从创立初期便坚持产学研的发展模式、差异化的创新模式，避免同质化竞争，切实考虑患者与临床需求，发力IVD原材料领域，研发各种关键原料，用自主创新产品替代进口产品。可正是因为这样的模式，导致在2018年，企业发展的关键时刻，由于研发成本大、周期长，短期不能产生效益，资金严重告急。历经几个月的努力，王忠亮仍没有敲开紧闭的资本大门。如此生死关头，高新担保为企业送来第一笔救急资金。

作为高新区管委会直属的政策性担保机构，在知晓企业的困难后，高新担保第一时间尽调企业，了解到企业研发团队实力强劲，核心团队成员均为医疗行业内的资深人士，专业能力覆盖产品研发、市场营销等方面，且企业拥有独立核心技术等的具体情况后，立刻为企业提供200万元“创新贷”担保服务，资金迅速到位，及时补充了企业研发投入和业务拓展所需的流动资金，并且三年间不间断为企业提供授信担保服务，担保发生额总计600万，保证了企业在生物原创领域的砥砺深耕。

如今，发展壮大的惠邦生物已围绕体外诊断产业构建IVD研发制造平台、检验设备研发制造平台、医用单克隆抗体研发制备平台三大核心技术平台，研发了针对肿瘤、妇幼保健、心血管、糖尿病肾病无创检测的一系列产品。获得国家重大专项一项、安徽现代医疗、安徽生物医疗新兴产业基地、安徽新型研发机构、中华医学会二等奖、华夏科技进步一、二等奖等等，其中部分项目纳入《合肥市十四五规划》。同时建立了博士后工作站。与首都医科大学、中国科技大学、安徽医科大学、安徽中医药大学建立了产学研合作模式。获得知识产权专利50余项，其中发明专利17项。2021年12月21日，惠邦生物DKD项目更是荣获2021年“创之星”杯中国体外诊断年度优秀创新产品金奖，这也是安徽省生物科技界企业首次获此殊荣。

At present, Huibang Biotechnology has completed the second round of financing, and the third round of financing is about to be completed, with a valuation directly exceeding 800 million. The company predicts that by 2023, it will meet the relevant requirements of the Science and Technology Innovation Edition, and the number of registered products will reach more than 50. The valuation exceeded 2 billion. Now, Huibang biological products have been distributed nationwide, and the channel construction has been initially completed. Huibang Biological New Industrial Park has started construction, and the new industrial park will fully increase production capacity. It is predicted that the output value will exceed 1 billion in 2023-2025.

At that time, people didn't know Lingyunmu, and they waited until Lingyun began to master. Accurate and detailed corporate due diligence, consideration of the corporate character and strength, and grasp of the core value of the company enable Hi-Tech Guarantee to respond quickly and provide the best financing solutions for corporate needs.

Sending charcoal in a timely manner is always more valuable than icing on the cake, which is also the significance of the existence of policy-based guarantee institutions. The high-tech guarantee has been with us for ten years, meeting the needs of enterprise development, and it is fruitful. Relying on policy support, strengthen the coverage of its own business, broaden the breadth and depth of guarantee services for small, medium and micro scientific and technological innovation enterprises, and play the role of "amplifier" of government financial funds to cultivate enterprises in greenhouses, rescue enterprises in water and fire, and save enterprises from life and death, highlighting state-owned enterprises Take charge. (Xue Yuchun)

(Editor in charge: Shen Ye)